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tus occurred at the time of presentation with AMI and at randomization Into VALIANT 
(median 4.6 days after presentation). Pts with a history of DM or insulin use prior to the 
qualifying MI were defined as previously known DM (n=3.421). Newly diagnosed DM 
(n=565) was defined as pts with DM. some of whom required diabetic therapy at random- 
ization; none had known DM at presentation. The primary outcome was 30-day mortality. 
Results: Compared with known DM, pts with new DM were younger and had less hyper- 
tension, dyslipidemia. or prior cardiovascular disease, but had similar LV ejection fraction 
and Killip class at presentation. As anticipated, known DM had a higher 30-day mortality 
than that for non-diabetics. However, the overall adjusted risk for death associated with 
new DM was more similar In magnitude to previous DM than that for non-diabetics. 
Conclusion : Previously known DM is associated with higher do-day mortality in high-nsk 
pts presenting with an AMI. Despite less cardiac co-morbidity, newly diagnosed DM has 
a similar prognosis to previously known DM. 
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Javier N. Guena. Juan J. Fuselli. Carlos P. Boissonnet. Enrique Fairman. Alfred0 
Piombo, Juan Gagliardi, DIC Group, Buenos Aires, Argentina 
Background: In diabetic (DBT) patients (p), atherosclerotic plaques contain more inflam- 
matory cells, suggesting higher plaque vulnerability. 
Purpose: To determine the prognostic value of HS C-reactive protein (CRP) in DBT p 
with unstable angina (UA), in order to predict in-hospital death and/or MI (D/Ml). 
Methods: Multicenter, prospective study. Of the 317 consecutive p herein included, 67 
were diabetic (21 .l%). CRP (positive value: higher tertile) and cTnT (positive value: 3 0.1 
@ml) were measured at admission >= 6 hours from qualifying episode. In-hospital D/MI 
rate was 7.6%. CRP values were higher in DBT p than in non-DBT p: 1.64 * 2.5 vs 1.23 
f 2.9 mg/dl: p=O.OOl, t test (prior log transformation). D/MI was higher in DBT p (14.9% 
vs 5.6%. p=O.OZ) and in p with CRP (+) (11.3% vs 5.7%, p=O.O4). In a logistic regression 
model including CRP and cTnT. cTnT (c) was predictive of D/Ml (OR 3.5, Cl 95% 1.5- 
6.2, p=O.O05), whereas CRP was not (~~0.3). In the subgroup of DBT p, the Incidence of 
D/Ml was 29.2% in p with CRP (+) vs 7.0% in those with CRP (-) (OR 5.5, Cl 95% 1.3- 
23.6, p=O.O4) (Figure). In the logistic regression analysis performed in DBT p, CRP (+) 
was an independent predictor of D/MI (OR 4.6, Cl 95% 1.03-20.4. p=O.O46), whereas 
cTnT (+) was not. 
Conclusion: CRP levels are higher in DBT p with unstable angina. This marker is a stron- 
ger predictor of D/Ml than cTnT(+) I” this subgroup of p. These data suggest that plaque 
inflammation plays a major role in the genesis and evolution of plaque instability in DBT p 
with unstable angina. 
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Insufficiency Study (OACIS) group, Osaka University, Osaka, Japan 
Background. Combination therapy with clopidogrel and aspirin is proved to be superior 
to aspirin alone in the prevention of major vascular ischemic events in patients with acute 
coronary syndrome without ST-segment elevation in the CURE trial. However, advan- 
tage of the combination use of thienopyridines in broad spectrum of acute myocardlal inf- 
arction (AMI) has not been thoroughly clarified. We evaluated the effect of combination 
use of ticlopidine on thirty-day mortality in patients of AMI including ST-elevation infarc- 
tion. Subjects and methods. Of consecutive 2723 patients with AMI who registered to 
Osaka Acute Coronary Insufficiency Study, 1709 patients receiving ticlopidine and/or 
aspirin were enrolled in this study. Patients receiving other antiplatelets were excluded. 
The patients were divided into two groups according to the antiplatelet therapy: group 
treated by aspirin alone (n=768) and group treated by combination use of aspirin and 
ticlopidine (n=941). We compared thirty-day clinical outcome and major adverse event 
between the two groups by unadjusted Kaplan-Meier method, chi-square analysis and 
multivariate logistic regression models. Results. Within thirty days of onset, combination 
therapy group showed significantly lower all-cause mortality (0.9% versus 5.9%, 
p<O.OOOl) than aspirin group. After adjustment by patient characteristics, coronary risk 
factors and therapies, combination therapy remained as an independent predictor of 
thirty-day mortality (Odds ratio 0.16, [95% Cl 0.0046.0.511. p=O.O023). Combination ther- 
apy also decreased a risk of a composite of cardiovascular death and Ml (Odds ratio 
0.45, [95% Cl 0.24-0.641, p=O.O13). Significant diflerences were not observed in major 
bleeding between the two groups. Conclusion.Though it is not in a randomized fashion, 
our data suggested that combination use of ticlopidine has more favorable effect on 
thirty-day prognosis than aspirin monotherapy when applied to a broad spectrum of 
patients with AMI. 
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Background: Since the advent of thrombolylic therapy, several studies have suggested 
that the rate of post-myocardial Infarction atrwentricular block (AVB) remains high and 
is associated with increased mortality. We sought to further delineate the predictors of 
AVB and the long-term mortality of patients developing AVB in the setting of ST-segment 
elevation myocardial infarction treated with thrombolytic therapy. 
Methods: We combined four studies of ST-segment elevation myocardial infarction 
(GUSTO-I, GUSTO-lib, GUSTO-III and ASSENT-II) into a large database (n=75.993). 
We identified independent predictors of second and third degree AVB and compared the 
6.month and l-year mortality rates of patients with AVB (5,251) with those of patients 
without AVB (70,742). 
Results: The incidence of AVB was 6.9%. Significant Independent predictors of AVB are 
summarized in the table. Adjusted mortality was significantly higher in patients with AVB 
than patients without AVB at 6 months (OR 1.6, 95% Cl 1.4-l .6) and at 12 months (OR 
1.3, 95% Cl 1.1-1.5). 
Conclusion: In the thrombolytic era, AVB is not only a common complication of ST-seg- 
ment elevation myocardial infarction, but portends higher mortality. Future studies should 
focus on determining therapies that are effective at reducmg the mortality rates of these 
patients. 
